Interferon-free Sofosbuvir containing treatment regimens in a real-life cohort of chronic Hepatitis C patients with cirrhosis
K Kozbial, C Freissmuth, R Al-Zoairy, S Moser, H Laferl, S Hametner, R Stauber, M Strasser, T Bamberger, S Beinhardt, A Stättermayer, R Stern, M Eder, M Mandorfer, H Zoller, W Vogel, I Graziadei, R Strassl, A Maieron, M Gschwantler, A Ferlitsch, M Peck-Radosa… · Zeitschrift für Gastroenterologie · 2015 · Heft 05
Bibliografische Angaben
Zusammenfassung
Background: Sofosbuvir (SOF), Simeprevir (SMV) and Daclatasvir (DCV) are reimbursed for chronic hepatitis C patients with advanced liver disease (F3, F4) and posttransplant patients in Austria. Real-life data in these patients are scarce and the optimal duration of treatment is still under debate. The aim of this study was to evaluate the efficacy of SOF based treatment regimens in an Austrian-wide multicenter real world setting of chronic hepatitis C patients with cirrhosis. Methods: 250 HCV monoinfected patients with cirrhosis (mean age: 56.5 ± 10.6 years, m/f: 167/83, treatment experienced: 161 [64%], prior f…